Arthur Kuan currently serves as Chief Executive Officer and Director on the Board at CG Oncology, a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition and development of novel immunotherapies, including an oncolytic virus for the treatment of bladder cancer and a variety of other solid tumor types. Arthur is a Founding Member of Ally Bridge Group, a global healthcare-focused investment platform, and plays an active role in managing the fund’s portfolio companies. Previously, Arthur was a member of Themes Investment Partners, a Private Equity fund based in Hong Kong, where he played a central role in coordinating cross-border technology transfer and regulatory submissions for portfolio companies. He began his career in an operational role at Dinova Capital, a Shanghai-based, medical technology incubator fund, evaluating medical device investment opportunities. Arthur received his MS in Biotechnology from the Johns Hopkins University and his BA in Biology from the University of Pennsylvania.​

© 2021 BioFutureTM. All Rights Reserved

Produced by